A notable study, the PRECISE Trial, investigated the catheter-based, convection-enhanced delivery (CED) of an interleukin 13–Pseudomonas exotoxin fusion protein (IL-13–PE) compared to Gliadel in patients with recurrent MG. The gene discussed is IL13; the disease is myasthenia gravis.